Trametinib

**Semantic type:** Organic Chemical|Pharmacologic Substance

**Definition:** An orally bioavailable inhibitor of mitogen-activated protein kinase kinase (MAP2K; MAPK/ERK kinase; MEK) 1 and 2, with potential antineoplastic activity. Upon oral administration, trametinib specifically binds to and inhibits MEK 1 and 2, resulting in an inhibition of growth factor-mediated cell signaling and cellular proliferation in various cancers. MEK 1 and 2, dual specificity serine/threonine and tyrosine kinases often upregulated in various cancer cell types, play a key role in the activation of the RAS/RAF/MEK/ERK signaling pathway that regulates cell growth.

**Synonyms:** - GSK 1120212 - GSK 212 - GSK-1120212 - GSK-212 - GSK1120212 - GSK212 - JTP 74057 - JTP-74057 - JTP74057 - MEK Inhibitor GSK1120212 - N-(3-{3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide - TRAMETINIB